Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study

World Journal of Gastroenterology

Volumn 11, Issue 48, 2005, Pages 7560-7563

  Sookoian, Silvia ^a   Fernández, María Alejandra ^b   Castaño, Gustavo ^c  

^a INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Hospital Interzonal Dr Jose Penna   (Argentina)

Author keywords

Angiotensin II; AT1R; Chronic liver disease; Hepatitis C; Liver fibrosis; Losartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; INTERFERON; LOSACOR; LOSARTAN; RIBAVIRIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIGITAL IMAGING; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION TEST; LIVER BIOPSY; LIVER BLOOD FLOW; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; MEAN ARTERIAL PRESSURE; ORTHOSTATIC HYPOTENSION; PILOT STUDY; RECEPTOR BLOCKING; SCORING SYSTEM; SUBENDOTHELIUM; SYSTOLIC BLOOD PRESSURE;

EID: 31644451945     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i48.7560     Document Type: Article

References (15)

1. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46
2. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, Colmenero J, Nicolas JM, Jimenez W, Weich N, Gutierrez-Ramos JC, Arroyo V, Rodes J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117-125
3. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H,Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-750
4. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Lai PB. Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regul Pept 2003; 116: 61-69
5. Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J, Vuillemin E, Gallois Y, Douay O, Chappard D, Cales P. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 2002; 37: 773-780
6. Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncol Rep 2005; 13: 491-495
7. Ushiki T. Collagen fibers, reticular fibers and elastic fibers. A comprehensive understanding from a morphological viewpoint. Arch Histol Cytol 2002; 65: 109-126
8. Fernadez A, Castano G, Sookoian S, Lemberg A, Amante M, Parisi C,Perazzo J. A new image analysis method for quantification of liver fibrosis. J Hepatol 2003; 38: 216-Abs.
9. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99: 1160-1174
10. Schneider AW, Kalk JF,Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-339
11. Castano G, Viudez P, Frider B, Sookoian S. Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2002; 122: 1544-1545
12. Sookoian S, Castano G, Garcia SI, Viudez P, Gonzalez C, Pirola CJ. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am J Gastroenterol 2005; 100: 636-642
13. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 2003; 98: 1371-1376
14. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225
15. Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y, Sakuta S. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 36: 1022